Novo Nordisk AS - Company Profile
Powered by
All the data and insights you need on Novo Nordisk AS in one report.
- Save hours of research time and resources with
our up-to-date Novo Nordisk AS Strategy Report
- Understand Novo Nordisk AS position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View more- Top 10 Pharmaceutical Companies in Europe in 2022 by Market Capitalization
- Top 10 Pharmaceutical Companies in the World in 2022 by Market Capitalization
- Top 10 Pharma Companies in Europe in 2021 by R&D Expenditure
- Top 10 Big Biopharma Companies (Large Pharma & Large Biotech) in Europe in 2021 by Revenues
Novo Nordisk AS (Novo Nordisk) is one of the leading global healthcare companies in diabetes care. Business performance of the diabetes and obesity care segment, focus on R&D activities, and Focus on GLP-1-based products are the major strengths of the company, even as its product recalls could be a major cause for concern. Novo Nordisk could benefit from the growing market for Parkinson’s disease, contracts and agreements, and strategic acquisitions. However, product patent expiry, operational risk, and competition and technological change could affect the company’s market position.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer